FDA clarifies compounded GLP-1 policies, warns telehealth companies

April 7, 2026

FDA Clarifies Policies on Compounded GLP-1s, Warns Companies

Eric Fader Rivkin Radler LLP + Follow Contact LinkedIn Facebook X Send Embed

On April 1, the U.S. Food and Drug Administration (FDA) clarified its policies on compounded drugs, including compounded versions of GLP-1 products. Compounders are permitted to produce copies of approved drugs only while those drugs are listed in FDA’s ​shortage database.

GLP-1 products are used primarily for weight loss and diabetes. They include semaglutide (used in the branded drugs Ozempic and Wegovy) and tirzepatide (used in Zepbound and Mounjaro), among others. The explosion in growth of direct-to-consumer marketing of GLP-1s for weight loss over the past few years caused a shortage of the drugs, and compounders stepped in to fill the void. However, compounded drugs are not FDA-approved.

Although FDA removed semaglutide from its shortage list in February 2025, some specific dosages of semaglutide, and certain dosages of tirzepatide (particularly starting doses), are still sometimes hard to find in the branded versions. Compounders can also produce “in-between” dosages that are not available at all in the branded drugs, and can add secondary ingredients like B-vitamins to create a “different” product to circumvent the prohibition on production of a compounded GLP-1.

Last month, FDA announced that it sent warning letters to 30 telehealth companies that FDA claimed were illegally marketing compounded GLP-1s. The main violations FDA identified were false or misleading claims that the compounded drugs were equivalent to FDA-approved drugs, and advertising suggesting that the telehealth companies did the compounding themselves.

Send Print Report

Related Posts

• FDA Issues Medical Device Safety Guidance For MRI Facilities
• FDA Warns That Topical Pain-Relief Products Containing CBD Violate FD&C Act
• FDA Announces Digital Health Center of Excellence

Latest Posts

• The “Mandated” New York S Corporation Election – Does Investment Income Include Gain from the Sale of Goodwill?
• FDA Clarifies Policies on Compounded GLP-1s, Warns Companies See more »

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Rivkin Radler LLP

Written by:

Rivkin Radler LLP Contact + Follow Eric Fader + Follow more less

PUBLISH YOUR CONTENT ON JD SUPRA

• ✔ Increased readership
• ✔ Actionable analytics
• ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Advertising + Follow Drug Approvals + Follow Drug Compounding + Follow Enforcement Actions + Follow False Advertising + Follow FDA Warning Letters + Follow Food and Drug Administration (FDA) + Follow New Guidance + Follow Pharmaceutical Industry + Follow Prescription Drugs + Follow Regulatory Oversight + Follow Regulatory Requirements + Follow Telehealth + Follow Unfair or Deceptive Trade Practices + Follow Warning Letters + Follow Administrative Agency + Follow Consumer Protection + Follow Health + Follow more less

Rivkin Radler LLP on:

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide